Company Overview of Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company’s lead product candidate ADS-5102, which completed the Phase II/III clinical trial for the treatment of Parkinson's disease, known as levodopa induced dyskinesia. Its product portfolio also includes memantine-based therapeutics, which include Namenda XR, a treatment of moderate to severe dementia associated with Alzheimer's disease; and Namzaric, a once-daily fixed-dose combination of Namenda XR, which is being co-developed with Forest Laboratories, Inc. The company was f...
1900 Powell Street
Emeryville, CA 94608
Founded in 2000
Key Executives for Adamas Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Total Annual Compensation: $748.8K
Chief Operating Officer
Total Annual Compensation: $436.1K
Senior Vice President of Product Development
Total Annual Compensation: $503.0K
Compensation as of Fiscal Year 2014.
Adamas Pharmaceuticals, Inc. Key Developments
Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc. Enter into a Settlement Agreement with Amneal Pharmaceuticals LLC and Related Companies and Subsidiaries
Sep 10 15
Allergan plc announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement agreement with Amneal Pharmaceuticals LLC and related companies and subsidiaries. The settlement relates to a patent infringement litigation brought by Forest and Adamas in response to Amneal's abbreviated new drug application (ANDA) seeking approval to market generic versions of Allergan's NAMENDA XR(R) (memantine hydrochloride) extended release capsules. It is Allergan's understanding that Amneal is the first applicant to file an ANDA containing a paragraph IV certification regarding NAMENDA XR. Specifically, under the terms of the settlement agreement, and subject to review of the settlement terms by the U.S. Federal Trade Commission, Forest and Adamas will grant Amneal a license to market generic versions of NAMENDA XR beginning on January 31, 2020, following receipt by Amneal of final approval from the U.S. Food and Drug Administration (FDA) on its ANDA for generic NAMENDA XR. Alternatively, under certain circumstances, Amneal has an option to launch an authorized generic version of NAMENDA XR(R) beginning on January 31, 2021. Other terms of the settlement were not disclosed. Similar patent infringement litigations brought by Forest, Adamas and Merz Pharma GmnH & Co. KgaA, against certain other companies that have filed ANDAs seeking approval to market generic versions of NAMENDA XR remain pending in the U.S. District Court for the District of Delaware. Allergan is committed to Alzheimer's patients and caregivers through the Company's continued support of NAMENDA XR, as well as the recent introduction of a new innovative treatment option, NAMZARIC(TM) (memantine hydrochloride extended-release and donepezil hydrochloride).
Adamas Pharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 11 15
Adamas Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of $398,000 compared with $25,154,000 for the same period a year ago. Loss from operations was $14,153,000 compared with income from operations of $16,719,000 for the same period a year ago. Loss before income taxes was $14,051,000 compared with income before income taxes of $16,607,000 for the same period a year ago. Net loss was $14,051,000 or $0.78 per diluted share compared with net income of $16,429,000 or $0.88 per diluted share for the same period a year ago.
For the six months, the company reported revenues of $624,000 compared with $25,330,000 for the same period a year ago. Loss from operations was $26,379,000 compared with income from operations of $11,028,000 for the same period a year ago. Loss before income taxes was $26,199,000 compared with income before income taxes of $10,228,000 for the same period a year ago. Net loss was $26,253,000 or $1.47 per diluted share compared with net income of $10,049,000 or $0.53 per diluted share for the same period a year ago. Net cash used in operating activities was $24,047,000 compared with net cash provided by operating activities of $14,168,000 for the same period a year ago. Purchases of property and equipment was $447,000 compared with $194,000 for the same period a year ago.
Adamas Pharmaceuticals, Inc. Announces the Completion of Recruitment of its Phase 3 EASE LID Study
Jul 9 15
Adamas Pharmaceuticals, Inc. announced the completion of recruitment of its Phase 3 EASE LID study. EASE LID is a confirmatory trial designed to evaluate the efficacy and safety of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a motor complication associated with the treatment of Parkinson's disease. EASE LID, which is enrolling approximately 120 individuals, is a 26-week multi-center, randomized, double-blind, placebo-controlled study assessing the efficacy of a 340 mg dose of ADS-5102 administered once daily at bedtime. The primary endpoint of EASE LID is a reduction in dyskinesia assessed by change from baseline to week 12 in UDysRS (a tool that assesses the disability and impairment of LID in Parkinson's disease) with a key secondary endpoint being change in ON time without troublesome dyskinesia as measured by patient diaries. Safety and tolerability are also being assessed. In addition to EASE LID, Adamas has two ongoing Phase 3 clinical trials of ADS-5102 for the treatment of LID in individuals with Parkinson's disease. These clinical trials were initiated following the completion of a Phase 2/3 study. Completed Phase 2/3 Trial: EASED, a randomized, placebo-controlled, multi-center study, evaluated patients with Parkinson's disease experiencing troublesome LID. Patients were randomized to receive placebo or to one of three dose levels of ADS-5102. As previously reported, ADS-5102 at 340 mg/day significantly reduced LID as measured by change in UDysRS over eight weeks versus placebo (primary endpoint, p=0.005). In addition, ADS-5102 increased ON time without troublesome dyskinesia by 3.8 hours, with 2.7 hours coming from a reduction in ON time with troublesome dyskinesia. Data also suggested that ADS-5102 was generally well tolerated and reported adverse events were consistent with Parkinson's disease and the known amantadine safety profile. Ongoing Phase 3 Studies: EASE LID 3, which is estimated to enroll approximately 70 patients. The 13-week multi-center, randomized, double-blind, placebo-controlled study will assess the efficacy of a 340 mg dose of ADS-5102 administered once daily at bedtime. The primary endpoint of EASE LID 3 is a reduction in dyskinesia assessed by changes in UDysRS with a key secondary endpoint being change in ON time without troublesome dyskinesia as measured by patient diaries. EASE LID 2, an open-label safety study, which is also open to patients from EASED, EASE LID and EASE LID 3.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|